Adopted as a "Model Project for Promoting Decarbonization throughout the Value Chain" by the Ministry of the Environment
～12 companies to participate in the formulation of common rules for calculating CO2 emissions in the pharmaceutical industry

　We are pleased to announce that the Carbon Neutral Group of the Japan Pharmaceutical Manufacturers Association (JPMA) Environmental Issues Study Committee has applied for the "Model Project for Promotion of Decarbonization throughout the Value Chain (Industry Group)" for fiscal 2025, which was publicly solicited by the Ministry of the Environment of Japan, and that the application has been informally selected.

　The following 12 companies, which are members of the Pharmaceutical Manufacturers Association of Japan (PMAJ), will participate in this project.

Astellas Pharma Inc., AstraZeneca Corporation, Eisai Co.

This project aims to reduce emissions throughout the value chain on an industry-wide basis, and supports efforts to establish industry-wide Scope 3 calculation and primary data acquisition rules and guidelines for engagement policies.

　This initiative will contribute to the realization of "Trust: Ensure ethics and transparency and become an industry trusted by society", one of the priority areas in the "Industrial Vision 2035" announced by the Pharmaceutical Manufacturers Association of Japan in February 2025. The knowledge gained through this project will be shared widely to contribute to solving environmental issues such as climate change, which has a serious impact on human health. By doing so, we aim to realize a sustainable society that supports a stable supply of pharmaceuticals.